van der Lugt J, Gorowara M, Avihingsanon A, Burger D, Ananworanich J, Sringam K, Kerr S, Wit F, Lange J, Ruxrungtham K
Reducing the boosting dose of ritonavir does not affect saquinavir plasma concentrations in HIV-1-infected individuals. [Journal Article, Research Support, Non-U.S. Gov't]
AIDS 2009 Jun 1; 23(9):1176-9.
Currently, the optimal boosting dose for saquinavir is unknown. Therefore, we evaluated the pharmacokinetics profiles in a cross over setting comparing saquinavir/ritonavir 1500/50 mg (plus NRTI backbone) to saquinavir/ritonavir 1500/100 mg in the same HIV-infected, Thai individuals. The 50% reduction of ritonavir boosting did not result in a change in the pharmacokinetics of saquinavir, whereas the ritonavir exposure was significantly lower when a dose of 50 mg was administered.
More from this journal |
